- Home
- ELVN vs PLSE Comparison
ELVN vs PLSE Comparison
Compare ELVN & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- PLSE
- Stock Information
- Founded
- ELVN 2016
- PLSE 2014
- Country
- ELVN United States
- PLSE United States
- Employees
- ELVN N/A
- PLSE N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- PLSE Medical/Dental Instruments
- Sector
- ELVN Health Care
- PLSE Health Care
- Exchange
- ELVN Nasdaq
- PLSE Nasdaq
- Market Cap
- ELVN 1.2B
- PLSE 1.1B
- IPO Year
- ELVN 2020
- PLSE 2016
- Fundamental
- Price
- ELVN $20.81
- PLSE $20.15
- Analyst Decision
- ELVN Strong Buy
- PLSE Buy
- Analyst Count
- ELVN 5
- PLSE 1
- Target Price
- ELVN $41.20
- PLSE $22.00
- AVG Volume (30 Days)
- ELVN 563.5K
- PLSE 259.9K
- Earning Date
- ELVN 11-12-2025
- PLSE 10-29-2025
- Dividend Yield
- ELVN N/A
- PLSE N/A
- EPS Growth
- ELVN N/A
- PLSE N/A
- EPS
- ELVN N/A
- PLSE N/A
- Revenue
- ELVN N/A
- PLSE N/A
- Revenue This Year
- ELVN N/A
- PLSE N/A
- Revenue Next Year
- ELVN $20.05
- PLSE $700.00
- P/E Ratio
- ELVN N/A
- PLSE N/A
- Revenue Growth
- ELVN N/A
- PLSE N/A
- 52 Week Low
- ELVN $13.30
- PLSE $13.77
- 52 Week High
- ELVN $30.03
- PLSE $25.00
- Technical
- Relative Strength Index (RSI)
- ELVN 51.84
- PLSE 70.79
- Support Level
- ELVN $19.02
- PLSE $17.10
- Resistance Level
- ELVN $20.66
- PLSE $19.94
- Average True Range (ATR)
- ELVN 1.00
- PLSE 0.83
- MACD
- ELVN 0.09
- PLSE 0.20
- Stochastic Oscillator
- ELVN 69.85
- PLSE 78.67
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.